Branchenkontext
Tyra Biosciences Inc [TYRA]
Zuletzt aktualisiert 24 Jun 2026 @ 16:00 (Exchange is closed)
Letzter Kurs: $30.37
1.03%
0.82 (↓)
GaG Algo Score™
v1.0
Kurz
0.82 (↓)
Mittel
0.29 (↓)
Lang
1.11 (↓)
KAUF
67.35%
Rendite 24.65%
VERKAUF
72.00%
Rendite 45.98%
Linie
Pivot-Daten
Pivot-Statistik
| Kennzahl | Durchschnitt | Median | Std.-Abw. |
|---|---|---|---|
| Gewinn % | 10.98% | 10.98% | 2.27% |
| Verlust % | -21.92% | -21.92% | 13.36% |
| Dauer | 12.8d | 11d | 9.6d |
| Gefundene Pivots gesamt | 5 |
| Gewinn-/Verlustphasen | 4 (2 Gewinn / 2 Verlust) |
| Letzter Pivot | Bottom @ $25.42 am 2026-06-10 |
| Änderung seit letztem Pivot | $4.64 (18.25%) |
Nächste Pivot-Prognose Letzter Kurs: $30.37
| Erwarteter nächster Typ | Top |
| Erwarteter Preis (Durchschn.) | $28.21 |
| Erwarteter Preis (Median) | $28.21 |
| Erwarteter Preisbereich (~68%) | $27.63 - $28.79 |
| Änderung zum Durchschnittsziel | $-2.16 (-7.11%) |
| Erwartetes Datum (Durchschn.) | 2026-06-22 |
| Erwarteter Datumsbereich (~68%) | 2026-06-13 - 2026-07-02 |
| Basis | Based on 2 historical gains (Avg: 10.98%, Median: 10.98%, StdDev: 2.27%) and duration (Avg: 12.8 days, StdDev: 9.6 days) |
| Hinweis | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Tyra Biosciences Inc edges lower, down -0.27%.
Tyra Biosciences Inc (TYRA) stock price showed a minimal loss on Tuesday after the stock fell $-0.0800 (-0.27%) from the previous session on normal volume. The stock moved in line with the falling NASDAQ that fell -0.43%. With 998 078 shares traded, volume yesterday reached $30.00M. This was 112 575 shares more than the prior day. Compared to the 10-day average of 1.14M shares, volume was the same as the average.
Tyra Biosciences Inc signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (0%), medium- (0%), and long-term (0%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Tyra Biosciences Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $33.80. approximately $3.74 (12.44%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $35.3. On a fall back there will be support at $10.3 The dis das resistance s110.3 -
Tyra Biosciences Inc Evaluation
- Kurz Score: 0.82
- Mittel Score: 0.29
- Lang Score: 1.11
Eigentümerfluss
GetAGraph InsiderPower
Transaktionen
167
Kaufkraft
143.16M
Verkaufskraft
29.61M
Zuverlässigkeit
100/100
Kauf / Verkauf
4.84
Hist. Korr.
-0.91
Letztes Signal
Buy 2026-05-20
Director 69
Officer 55
Executive 40
Other 3
2026-05-28
Ra Capital Management, L.p. Director
Buy 13 160
2026-05-28
Verjee Rehan Director
Buy 13 160
2026-05-28
Moran Susan Director
Buy 13 160
2026-05-28
Simson Jake Director
Buy 13 160
2026-05-28
Gulfo Adele M. Director
Buy 13 160
2026-05-28
More Robert J Director
Buy 13 160
Beziehungsprofil
Korrelationsbild
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.72% <strong>$30.61</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
17.39%
Of outstanding shares
Short float
25.47%
Of tradable float
Days to cover
13.12
Short interest divided by average volume
Squeeze probability
98.20%
+15.08% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
3
Avg. surprise
5.20%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-05 | - | - | - | - |
| Q2/2025 | 2025-08-06 | - | $-0.550 | - | - |
| Q1/2025 | 2025-05-08 | $-0.470 | $-0.490 | 4.08% | - |
| Q4/2024 | 2025-03-27 | $-0.430 | $-0.480 | 10.42% | - |
| Q3/2024 | 2024-11-07 | $-0.410 | $-0.400 | -2.50% | - |
| Q2/2024 | 2024-08-07 | $-0.320 | $-0.410 | 21.95% | - |
| Q1/2024 | 2024-05-09 | $-0.350 | $-0.460 | 23.91% | - |
| Q4/2023 | 2024-03-19 | $-0.530 | $-0.480 | -10.42% | 502 000 |
Analyst view
Analyst targets
Consensus
$50.50
Median
$51.50
Low
$42.00
High
$59.00
News flow
Latest company news
Market coverage
prnewswire.com TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY May 21, 2026 fool.com Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares May 17, 2026 seekingalpha.com Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript May 13, 2026 prnewswire.com Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights May 13, 2026Company releases
Company context
Company profile
Börse:
NASDAQ
Sektor:
Healthcare
Branche:
Biotechnology
Currency
USD
Tyra Biosciences Inc is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology Its flagship product candidate TYRA300 is a highly selective inhibitor of fibroblast growth factor receptor FGFR3 specifically engineered for the treatment of muscleinvasive bladder cancer Beyond this the company is advancing a pipeline of programs addressing other critical conditions including FGFR2related intrahepatic cholangiocarcinoma FGFR3associated achondroplasia REarranged during transfection RET kinase aberrations and various FGFR4driven cancers Tyra also leverages its proprietary SNAP platform designed to accelerate structural drug design through an iterative molecular snapshot approach Founded in 2018 Tyra Biosciences maintains its headquarters in Carlsbad California
Navigation